Qualigen-Logo-Tag.png
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
01 déc. 2021 15h25 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain...
ritter.jpg
Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018
28 août 2018 13h31 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split
22 mars 2018 11h35 HE | Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
01 mars 2018 16h20 HE | Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017
29 nov. 2017 09h30 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress
02 nov. 2017 16h52 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
31 oct. 2017 06h45 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
03 oct. 2017 12h00 HE | Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...